Nexus and Nevakar face off over hypotension drug
19-08-2021
Federal Circuit invalidates cardiovascular diagnostics patents
19-06-2017
Novartis in $1bn cardiovascular deal with Ionis and Akcea
20-02-2017
20-11-2020
Explode / Shutterstock.com
US cardiovascular therapies company Medicure has settled a patent infringement dispute with rival Nexus Pharmaceuticals.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Medicure, Nexus, Aggrasat, generics, licence, patent infringement, cardiovascular, ANDA, FDA, US District Court for the Northern District of Illinois